Oral spore-forming probiotic supplement

Spore-Based Probiotic

Spore-based probiotics are Bacillus spore-formers; the app lists a 48-hour half-life, and none of the studies cited reports one.

Moderate evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Spore-Based Probiotic after one dose: 50% at ~48 h, 25% at 96 h, 12.5% at 144 h.

Drawn from the half-life in the app's model, ~48 h. The model's figures

The app's entry covers Bacillus coagulans, Bacillus subtilis and Bacillus clausii spore-formers taken by mouth. A 2017 review by Bernardeau and colleagues (Journal of Food Science and Technology) says the composition of Bacillus spores "provides high tolerance to the acidic conditions in the stomach upon ingestion".1 Perotti and colleagues use the name Heyndrickxia coagulans for the species formerly called Bacillus coagulans, and some trials below use the older name.2

The trials described below enrolled between 24 and 144 adults in the groups analysed or enrolled, and each tests one named strain or product. Their reports name these funders: MY HEALTH (Wauters), Unique Biotech Ltd. (Madempudi), BIO-CAT (Garvey), Perfetti Van Melle S.p.A. (Perotti) and Ganeden Biotech (Kalman).3,4,5,2,6 The app grades the evidence for spore-based probiotics as moderate.

Bernardeau and colleagues write that "the spores are metabolically quiescent" and that a "metabolically active state" is needed "to perform certain probiotic functions".1 That review also tabulates a laboratory model of the human stomach and small intestine (TIM-1), in which 70.4% of Bacillus coagulans GBI-30 spores survived after 6 hours; this is a model result, not a measurement in people.1 Mazzantini and Ghelardi (Nutrients, 2026) report that "Spores of A. clausii were reported to survive in acidic environments, in the presence of bile and anoxic conditions".7 Tam and colleagues (Journal of Bacteriology, 2006) dosed mice with Bacillus subtilis spores and wrote that "Significant levels of germination and sporulation were documented" in the mouse gut.8 They suggested, from the mouse results and from isolates that formed spores in almost half the time required for the laboratory isolate, that "spores are not transient passengers of the gastrointestinal tract but have adapted to carry out their entire life cycle within this environment".8 In 30 healthy volunteers who had not taken probiotic supplements for 12 months, the same group reported that spores could readily be recovered, with counts in the range of 10^3 to 10^8 CFU/g of feces (10^4 described as a realistic mean), and described the colonies as "most likely to be species of Bacillus".8 In people, the Perotti study (below) reported that "bacterial spores germinated in all volunteers" given one Heyndrickxia coagulans strain.2 Garvey and colleagues, discussing their own trial, state that "the exact mechanism by which BS50 improved GI symptoms remains unknown".5

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~48 h
Bioavailability
95%
Typical dose
2–10 billion CFU/day
Route
Oral
Time to peak
~4 h

A live-organism supplement is not measured the way a drug is: the human studies below count the strain in stool rather than report a plasma half-life or an absorbed fraction. The second column of the table holds the app's figures, shown beside what the studies report.

Table 3.1Half-life and pharmacokinetics3 rows
ParameterApp's figureReported in the studies
Half-lifeAbout 2 days (48 hours)No half-life figure is given in the studies cited. In the Perotti trial of 24 adults, viable strain SNZ1969 was "still detectable in the feces of approximately half of the subjects at the end of the follow-up phase", two weeks after the last serving2
Bioavailability95%No absorbed-fraction figure is given in the studies cited. In the Hanifi trial (n=81), faecal viable counts of B. subtilis R0179 rose with dose, to 6.4±0.1 log10 cfu/g at 10×10^9 cfu/day against 1.1±0.1 in the placebo group9
Time to peakAbout 4 hoursNo time-to-peak figure is given in the studies cited. Perotti and colleagues describe another group's report that orally ingested B. subtilis DE111 spores "could germinate in the small intestine of humans within 3 h after ingestion", which is a germination time and not a peak concentration2

The app's note says these products survive stomach acid "where Lactobacillus/Bifidobacterium capsules don't" and that they are transient and re-dosed daily. No trial read compared spore-formers head to head with Lactobacillus or Bifidobacterium capsules; the Perotti authors compare their stool recovery with published results for Lacticaseibacillus paracasei Shirota, Lacticaseibacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB12 and call it "comparable to or even superior to" them, and the Perotti trial detected the strain in stool for two weeks after intake stopped in about half of 24 adults, so the sources do not settle the app's wording on either point.

4

Human studies

Table 4.1Human studies8 rows
Study and yearDesignPeopleDose and lengthMain result
Wauters and colleagues, Lancet Gastroenterology and Hepatology 20213Single-centre, randomised 1:1, double-blind, placebo-controlled pilot trial; funded by MY HEALTH368 adults with functional dyspepsia (75% women, mean age 40.1 years)3Bacillus coagulans MY01 and Bacillus subtilis MY02, 2.5 × 10^9 CFU per capsule, twice per day, or placebo; 8 weeks, then 8 weeks open label3Responders 12 (48%) of 25 against 6 (20%) of 30 (relative risk 1.95, 95% CI 1.07 to 4.11; p=0.028); adverse events in 5 (16%) of 32 against 12 (33%) of 363
Madempudi and colleagues, Scientific Reports 20194Randomised 1:1, double-blind, placebo-controlled, two centres in Mumbai; funded by Unique Biotech Ltd.4Adults aged 18 to 60 with irritable bowel syndrome (Rome III), a weekly average worst abdominal pain score of 3.0 or more on an 11-point scale and an average of fewer than 3 complete spontaneous bowel movements per week; 136 randomised, 108 completed the study (per-protocol population) and 28 dropped out4B. coagulans Unique IS2, 2 billion CFU daily, or placebo; 8 weeks4At week 8, 45 (84.91%) against 7 (12.73%) had 50% or more pain reduction; at week 4, 5 (9.43%) against 2 (3.64%); no significant change in serum cytokines4
Garvey and colleagues, Gut Microbes 20225Randomised 1:1, double-blind, placebo-controlled, parallel; funded by BIO-CAT, which makes the strain576 healthy adults, all completed5Bacillus subtilis BS50, 2 × 10^9 CFU per day, or placebo; 6 weeks5Composite bloating, burping and flatulence score improved in 47.4% against 22.2% (odds ratio 3.2, 95% CI 1.1 to 8.7, p=.024); bloating alone 31.6% against 13.9% (p=.071); no effect on bowel movements or stool consistency5
Perotti and colleagues, Current Research in Food Science 20242Single-arm, open-label recovery study; funded by Perfetti Van Melle S.p.A.224 healthy adults aged 18 to 65 (mean age 34 years)2One gummy serving per day (24 g, label claim of at least one billion CFU) for 2 weeks, then 2 weeks follow-up2Viable strain recovered from all 24 and spores germinated in all; no adverse events reported; no health outcome tested2
Hanifi and colleagues, Beneficial Microbes 20159Randomised, double-blind, placebo-controlled, four arms; an author is at Lallemand Health Solutions, and the record read gives no funding statement981 healthy adults aged 18 to 509B. subtilis R0179 at 0.1, 1.0 or 10×10^9 cfu per capsule per day, or placebo; 4 weeks9General wellness and GI function not affected at any dose; faecal counts rose with dose9
Kalman and colleagues, BMC Gastroenterology 20096Randomised, double-blind, placebo-controlled, two sites; funded by Ganeden Biotech661 adults with post-prandial gas-related symptoms and no GI diagnosis (30 product, 31 placebo; all 30 on product and 30 of 31 on placebo completed the protocol)6One capsule daily, 2.0 × 10^9 CFU per capsule together with an enzyme blend; four weeks6GSRS abdominal pain p = 0.046 and total score p = 0.048 against placebo; abdominal distension p = 0.061; the differences were significant or nearly significant in three of the 12 variables, and the authors note "A strong placebo effect was evident which could explain the lack of statistical significant differences between the groups for many of the efficacy variables"6
LeMoire and colleagues, Beneficial Microbes 202510Randomised 1:1, double-blind, placebo-controlled; authors include three at PepsiCo Inc., and the record read gives no funding statement10144 healthy adults with infrequent bowel movements10B. coagulans Unique IS2, 2 billion CFU per day, or placebo; 4 weeks after a 2-week run-in10Bowel movement frequency showed a significant increase after 4 weeks of supplementation (P = 0.037; the record does not state the comparison); stool consistency better than placebo after 4 weeks (P = 0.018); no effect on GI symptoms, quality of life or gut microbiota composition10
Registry entry NCT01184456, AIDS Healthcare Foundation, results section posted 201911Phase 2 randomised, parallel, quadruple-masked; collaborator Ganeden Biotech, Inc.11Adults with HIV infection and gastrointestinal symptoms11One capsule per day of 2 billion CFU GanedenBC30 or placebo for 90 days11No results: the entry states "all efforts to locate the data have been exhausted and no data is available"11

Deeper analysis: Wauters, functional dyspepsia (2021)

Wauters and colleagues (University Hospitals Leuven, Lancet Gastroenterology and Hepatology, 2021) ran a single-centre, double-blind, placebo-controlled pilot trial that took place in Leuven, Belgium.3 Adults with functional dyspepsia by Rome IV criteria, on or off proton-pump inhibitors, were randomised 1:1 and stratified by proton-pump inhibitor status.3 Exclusions covered abdominal surgery, diabetes, coeliac or inflammatory bowel disease, active psychiatric conditions, and immunosuppressant drugs, antibiotics or probiotics in the past 3 months.3 The primary endpoint was a decrease of at least 0.7 in the postprandial distress syndrome score of the Leuven Postprandial Distress Scale, in patients with a baseline score of 1 or greater.3 Of 68 patients, 32 were assigned to probiotics and 36 to placebo.3 Responders numbered 12 (48%) of 25 on probiotics and 6 (20%) of 30 on placebo, with a relative risk of 1.95 (95% CI 1.07 to 4.11; p=0.028).3 The responder denominators (25 and 30) are smaller than the numbers randomised (32 and 36); the PubMed record defines the primary endpoint in patients with a baseline score of 1 or greater but does not itself explain the difference.3 Adverse events occurred in five (16%) of 32 on probiotics and 12 (33%) of 36 on placebo, and two serious adverse events in the open-label phase (appendicitis and syncope) were "assessed as unlikely to be related to the study product".3 The authors call it "an exploratory study" and report that participants "had potentially beneficial immune and microbial changes"; the PubMed record, which is the only text read, gives no figures for those secondary results.3 The record contains no separate limitations passage, so the authors' own limitations beyond the words "pilot" and "exploratory" are not stated in the text read.3 Funding is listed as MY HEALTH, two authors are affiliated with MY RESEARCH in Diepenbeek, and the authors declare "no competing interests".3

Deeper analysis: Madempudi, irritable bowel syndrome (2019)

Madempudi and colleagues (Scientific Reports, 2019) tested Bacillus coagulans Unique IS2 in adults with irritable bowel syndrome at two sites in Mumbai, India.4 After a 2-week placebo run-in of 153 patients, 136 who met the compliance criteria were randomised to B. coagulans Unique IS2 (2 billion CFU) or placebo daily for 8 weeks.4 Of the 136 randomised, 108 (53 on the probiotic and 55 on placebo) completed the study as the per-protocol population, and the other 28 dropped out due to protocol deviations (11), violations (2) and unavailability during follow-up visits (15).4 The primary efficacy outcomes were pain intensity on an 11-point numerical rating scale and frequency of complete spontaneous bowel movements.4 Mean baseline pain fell from 8.2 to 3.4 with the probiotic and from 8.3 to 6.7 with placebo at week 8.4 At week 8, 45 (84.91%) of 53 on the probiotic and 7 (12.73%) of 55 on placebo had a pain reduction of 50% or more, while at week 4 the figures were 5 (9.43%) and 2 (3.64%).4 A complete spontaneous bowel movement responder rate was seen in 42 (79.25%) on the probiotic and 22 (40.00%) on placebo.4 Serum cytokine results were null: "No significant changes were observed in serum TNF-α, IFN-γ, IL-6, IL-10 and IL-12 levels with B. coagulans Unique IS2 treatment as compared with placebo".4 "No adverse events were recorded" in either group.4 The authors write that "as probiotic effects are strain specific" their conclusion concerns this strain.4 The full text does not use the word limitation, and the passages read do not set out limitations of the authors' own.4 The study was "fully funded by Unique Biotech Ltd.", three authors (R.S.M., J.J.A. and J.N.) are employed by it, and the authors state that "Each of the authors or their respective organizations were financially compensated by Unique Biotech Ltd for their contribution in the study".4

Deeper analysis: Garvey, Bacillus subtilis BS50 in healthy adults (2022)

Garvey and colleagues (BIO-CAT Microbials and Biofortis Research, Gut Microbes, 2022) randomised 76 healthy adults to Bacillus subtilis BS50 at 2 × 10^9 CFU per day or placebo for 6 weeks.5 The primary outcome was the share of participants improving on a 7-day, 3-item composite of flatulence, bloating and burping, with a sample of 64 expected to give 80% power.5 All 76 completed the protocol, and the intent-to-treat analysis included everyone randomised.5 The composite improved in 47.4% on BS50 against 22.2% on placebo (odds ratio 3.2, 95% CI 1.1 to 8.7, p=.024).5 Burping improved in 44.7% against 22.2% (p = .041) and bloating in 31.6% against 13.9% (p = .071), "without affecting other symptoms".5 The authors report no effect on bowel movements, stool consistency or bowel-movement symptoms, and no significant changes in plasma lipids or inflammation markers, adding that the trial "was not powered to assess these markers".5 For safety, five adverse events (four mild and one moderate) were reported by four participants; four were judged by the study physician as not related to the product, and the remaining one, judged possibly related, was reported by a participant in the placebo group, and the authors call BS50 "well-tolerated and safe" in healthy adults at this dose and duration.5 BIO-CAT, Inc. provided funding, two authors are employees of BIO-CAT entities, BIO-CAT Microbials manufactures the strain and filed a patent application related to the findings, and "The funders were involved in the design of the study, in the writing of the manuscript, and in the decision to publish the results".5

Deeper analysis: Perotti, strain recovery in stool (2024)

Perotti and colleagues (University of Milan, Current Research in Food Science, 2024) gave 24 healthy adults one gummy serving a day of Heyndrickxia coagulans SNZ1969 spores for two weeks and followed them for two more weeks.2 The design was "a single-arm, open-label microbiological trial", so there was no placebo group and no health outcome was tested.2 Two volunteers already carried H. coagulans before the study, "albeit at concentrations below 100 CFUs per gram of feces".2 All 24 completed the 2-week intervention, one withdrew on day 15 with gastrointestinal flu, and no volunteer reported an adverse event.2 Vegetative forms made up 18% to 75% of the strain's counts, and in 39 of 412 samples (about 9%) no vegetative form was detected even though spores were present.2 Viable strain was still detectable in about half of the subjects at the end of follow-up.2 The authors state limits on their own data: "the data from this study do not allow us to determine how many of the ingested spores were actually able to germinate", and "we cannot establish the exact duration of its intestinal persistence".2 They add that "further controlled trials are needed to establish any potential health benefits for the consumer from ingesting this probiotic product".2 Perfetti Van Melle S.p.A. provided financial support, two authors are employed by it, and one author "served as a consultant" to it while the study was conducted.2

5

Doses reported in studies and on labels

The app's typical range is 2 to 10 billion CFU per day; the trials below used from 0.1 to 10 billion CFU per day of a named strain or product, and no regulator label for a spore-based probiotic was read.

Table 5.1Doses reported in studies and on labels9 rows
StudyStrain and productAmount reportedLength and people
Wauters 20213Bacillus coagulans MY01 and Bacillus subtilis MY022.5 × 10^9 CFU per capsule, twice per day8 weeks, 68 adults with functional dyspepsia
Madempudi 20194Bacillus coagulans Unique IS22 billion CFU daily8 weeks, adults with irritable bowel syndrome (108 analysed)
Garvey 20225Bacillus subtilis BS502 × 10^9 CFU per day6 weeks, 76 healthy adults
Hanifi 20159Bacillus subtilis R01790.1, 1.0 or 10 × 10^9 cfu per capsule per day, against placebo4 weeks, 81 healthy adults
LeMoire 202510Bacillus coagulans Unique IS22 billion CFU per day4 weeks, 144 healthy adults with infrequent bowel movements
Kalman 20096Bacillus coagulans GBI-30, 6086 with an enzyme blend2.0 × 10^9 CFU per capsule, one capsule daily4 weeks, 61 adults with gas-related symptoms
Perotti 20242Heyndrickxia coagulans SNZ1969 in gummy candyOne 24 g serving per day; label claim at least one billion CFU per serving2 weeks plus 2 weeks follow-up, 24 healthy adults
Lefevre 201712Bacillus subtilis CU12 × 10^9 spores per day40 days in total (four 10-day periods with 18-day washouts), healthy elderly subjects
Registry NCT0118445611GanedenBC30 (GBI-30, PTA-6086)1 capsule per day containing 2 billion CFU90 days, adults with HIV infection and GI symptoms; no data available

Several of the reports read describe no adverse events, and each covers a named strain, blend or product at the dose and duration it tested. In Wauters, adverse events occurred in 5 of 32 on probiotics and 12 of 36 on placebo, and the two serious events (appendicitis and syncope) were in the open-label phase.3 In Garvey, five adverse events (four mild and one moderate) were reported by four participants, and the one judged possibly related to the product was in a participant on placebo.5 A trial of a three-strain blend of Bacillus coagulans, clausii and subtilis (Soman and Swamy, 2019, 60 adults, authors at Sanzyme Biologics) and the Perotti single-arm trial each reported no adverse events.13,2 LeMoire and colleagues state that Unique IS2 "was safe and well tolerated over the 4 weeks of supplementation".10 Lefevre and colleagues report that Bacillus subtilis CU1 "was safe and well-tolerated" in elderly subjects, without "undesirable physiological effects on markers of liver and kidney function, complete blood counts, hemodynamic parameters, and vital signs"; four of the authors list Lesaffre Human Care as their affiliation.12 A 2022 review by Todorov and colleagues states that "many questions have been raised regarding their safety and the relevance of spore formation in the practical application of this group of microorganisms".14

7

Bloodwork and markers

The app lists no health markers to monitor for this entry. In Garvey (76 adults, 6 weeks) there were "no clinically meaningful changes in clinical chemistry, hematology, plasma lipids and intestinal permeability and other inflammation markers", with albumin changes from baseline in both groups described as minor, and Madempudi reported normal haematology and no significant change in serum cytokines.5,4 Garvey notes an IL-10 increase with BS50 as "suggested (p = .13 for ITT; p = .047 for PP)", from a trial the authors say was not powered for inflammation markers.5

8

Regulatory and anti-doping status

Perotti and colleagues state that Heyndrickxia coagulans "has been included in the Qualified Presumption of Safety (QPS) list by the European Food Safety Authority (EFSA)"; the EFSA document itself was not read.2 The retrieved text of the WADA 2026 Prohibited List, about 38,800 characters, contains no occurrence of "probiotic", "bacteri" or "microorganism"; that retrieved text may not be the complete list, so this is not a statement of any product's status.15 No US FDA or EMA product document for a Bacillus probiotic was read for this entry.

None of the studies cited reports a half-life, absorbed fraction or time to peak concentration for spore-based probiotics, so the app's figures of 48 hours, 95% and 4 hours have no study figure beside them. Perotti and colleagues could not say how many ingested spores germinated or how long the strain persists beyond two weeks of follow-up.2 Madempudi and colleagues write that "probiotic effects are strain specific" in framing their conclusion around B. coagulans Unique IS2; the other trials here tested different strains, products or blends.4 The registered phase 2 trial NCT01184456 posted a results section with the statement that no data is available, so its 90-day outcome in adults with HIV infection is unknown.11 The trials cited enrolled 24 to 144 adults, gave the product for 2 weeks to 16 weeks including open-label phases, and most were funded by or had authors tied to a company with an interest in the product, and the app's note naming specific commercial products (Seed DS-01, Just Thrive) is not supported by any study read.

What is the half-life of a spore-based probiotic?

The app lists about 48 hours, and none of the studies cited reports a half-life. In the Perotti trial, viable Heyndrickxia coagulans SNZ1969 was still detectable in the feces of approximately half of 24 adults two weeks after the last serving.2

What is the bioavailability of a spore-based probiotic?

The app lists 95%, and none of the studies cited reports an absorbed fraction. Hanifi and colleagues measured stool counts instead, and these rose with the daily dose of Bacillus subtilis R0179 from 4.6 to 6.4 log10 cfu/g.9

Do Bacillus spores survive stomach acid?

A 2017 review states that the composition of Bacillus spores "provides high tolerance to the acidic conditions in the stomach upon ingestion".1 In a laboratory model of the human stomach and small intestine, 70.4% of Bacillus coagulans GBI-30 spores survived after 6 hours, and in the Perotti trial viable strain was recovered from the feces of all 24 volunteers.1,2

Do spore probiotics germinate in the human gut?

In the Perotti trial of 24 healthy adults, "bacterial spores germinated in all volunteers", judged from vegetative cells in stool.2 The authors state that the data do not allow them to determine how many ingested spores germinated.2

Did a spore-based probiotic improve irritable bowel syndrome symptoms in a trial?

In the Madempudi trial, 45 (84.91%) of 53 adults on Bacillus coagulans Unique IS2 and 7 (12.73%) of 55 on placebo had a pain reduction of 50% or more at week 8; these are the 108 of 136 randomised adults who completed the study, and 28 dropped out.4 The trial was funded by Unique Biotech Ltd., and at week 4 the figures were 5 (9.43%) and 2 (3.64%).4

Did spore-forming probiotics help functional dyspepsia in a trial?

In the Wauters pilot trial of 68 adults, 12 (48%) of 25 on the probiotics and 6 (20%) of 30 on placebo were responders (relative risk 1.95, 95% CI 1.07 to 4.11).3 The authors describe it as an exploratory study funded by MY HEALTH.3

Is a spore-based probiotic banned by WADA?

The retrieved text of the WADA 2026 Prohibited List contains no occurrence of "probiotic", "bacteri" or "microorganism", though that text may not be the complete list.15 This is a search result on retrieved text and not a statement of any product's anti-doping status.

12

References

  1. Bernardeau M, et al. Importance of the gastrointestinal life cycle of Bacillus for probiotic functionality. J Food Sci Technol 2017. PMC5502041
  2. Perotti S, et al. Human in vivo assessment of the survival and germination of Heyndrickxia coagulans SNZ1969 spores delivered via gummy candies. Curr Res Food Sci 2024. PMID 39071473
  3. Wauters L, et al. Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2021. PMID 34358486
  4. Madempudi RS, et al. Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. Sci Rep 2019. PMID 31434935
  5. Garvey SM, et al. The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial. Gut Microbes 2022. PMID 36269141
  6. Kalman DS, et al. A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol 2009. PMID 19922649
  7. Mazzantini D, et al. Spore-Forming Probiotics and Their Mechanisms of Action: A Particular Focus on Alkalihalobacillus clausii. Nutrients 2026. PMID 42123979
  8. Tam NK, et al. The intestinal life cycle of Bacillus subtilis and close relatives. J Bacteriol 2006. PMID 16547057
  9. Hanifi A, et al. Evaluation of Bacillus subtilis R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults. Benef Microbes 2015. PMID 25062611
  10. LeMoire A, et al. Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial. Benef Microbes 2025. PMID 40456531
  11. AIDS Healthcare Foundation. A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System. ClinicalTrials.gov NCT01184456. NCT01184456
  12. Lefevre M, et al. Safety assessment of Bacillus subtilis CU1 for use as a probiotic in humans. Regul Toxicol Pharmacol 2017. PMID 27825987
  13. Soman RJ, et al. A prospective, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of SNZ TriBac, a three-strain Bacillus probiotic blend for undiagnosed gastrointestinal discomfort. Int J Colorectal Dis 2019. PMID 31686199
  14. Todorov SD, et al. Bacillus spore-forming probiotics: benefits with concerns? Crit Rev Microbiol 2022. PMID 34620036
  15. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list